戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 -binding fluorochromes and a monoclonal anti-double-stranded DNA antibody.
2 e presence of antinuclear antibodies or anti-double-stranded DNA antibodies.
3  parameters including seroconversion of anti-double-stranded DNA antibodies.
4 years, is characterized by the production of double-stranded DNA antibodies.
5 he 8.12 idiotype, which is expressed on anti-double-stranded-DNA antibodies.
6 with lupus nephritis, and patients with anti-double-stranded DNA antibodies (adjusted HR approximatel
7  the absence of a significant change in anti-double-stranded DNA antibody and complement levels.
8  with the presence of pathogenic anti-dsDNA (double-stranded DNA) antibodies, and provided spontaneou
9                    Lupus-associated IgG anti-double-stranded DNA antibodies are thought to be pathoge
10 easing immune complex generation, using anti-double-stranded DNA antibody as a biomarker; and (iii) p
11 -stranded DNA antibodies, deposition of anti-double-stranded DNA antibody complexes, complement activ
12 immune activation and the generation of anti-double-stranded-DNA antibodies, critically aggravating a
13                               Levels of anti-double-stranded DNA antibodies decreased by a median of
14 ell-B cell collaboration, production of anti-double-stranded DNA antibodies, deposition of anti-doubl
15  (antinuclear antibodies >/=1:80 and/or anti-double-stranded DNA antibodies >/=30 IU/ml) at baseline
16 rcent (at a dilution of 1:120 or more), anti-double-stranded DNA antibodies in 55 percent, anti-Ro an
17  MEK inhibitor was sufficient to induce anti-double-stranded DNA antibodies in a murine model of drug
18 rked female predominance, appearance of anti-double-stranded DNA antibodies in young adulthood, intra
19 tter than C3, plasma C4d, Bb, C5b-9 and anti-double-stranded DNA antibody in distinguishing patients
20 um complement component C3 and elevated anti-double-stranded DNA antibody levels at baseline improved
21 al practice, and we continue to rely on anti-double-stranded DNA antibody levels to assess serologic
22       Lymphocyte counts, Ig levels, and anti-double-stranded DNA antibody levels were available as pa
23 en) PCs and serum IgG antichromatin and anti-double-stranded DNA antibody levels were lower in NZM.Ba
24 reatment did not reduce serum levels of anti-double-stranded DNA antibodies or renal immune complexes
25 ing levels of IgG anti-chromatin and/or anti-double-stranded DNA antibodies or with amounts of these
26 ctivity was associated with anti-Ro and anti-double-stranded DNA antibodies (P = 4.6 x 10(-18) and P
27           Formation of TLS was found in anti-double-stranded DNA antibody-positive mice, and the stru
28 sgenic BALB/c donors induced lupus with anti-double stranded DNA antibodies, proteinuria, and immune
29 d between the levels of anti-Scl-70 and anti-double-stranded DNA antibodies (r = 0.558, P < 0.001).
30 renal disease, and had higher titers of anti-double-stranded DNA antibodies than wild-type MRL/lpr mi
31 cations, but correlated positively with anti-double-stranded DNA antibody titers among SLE patients a
32 es from 12 to 5 (P < 0.0001) and median anti-double-stranded DNA antibody titers from 106 to 42 IU/ml
33 Deficiency of CAD resulted in increased anti-double-stranded DNA antibody titers in lupus-prone mice.
34 bone marrow reduced atherosclerosis and anti-double-stranded DNA antibody titers.
35 plaque growth, associated with enhanced anti-double-stranded-DNA antibody titers.
36                          Positivity for anti-double-stranded DNA antibodies was associated with the e
37           The variation in the level of anti-double-stranded DNA antibody was different in individual
38                                         Anti-double-stranded DNA antibodies were associated with rena
39                            Accordingly, anti-double-stranded DNA antibodies were elevated in patients
40 mplement C3, C4, and CH50 and titers of anti-double-stranded DNA antibodies were normalized after tre
41                                         Anti-double-stranded DNA antibodies, with a mean onset 2.2 ye